Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients

A Phase Ib/II Study of Docetaxel With or Without Buparlisib as Second Line Therapy for Patients With Advanced or Metastatic Squamous Non-small Cell Lung Cancer

This is a multi-center, open-label Phase Ib dose escalation part followed by a randomized double-blinded placebo controlled Phase II part.

The Phase Ib part will determine the Maximum Tolerated Dose (MTD)/Recommended Phase II Dose (RP2D) of buparlisib in combination with docetaxel. Subsequently the MTD/RP2D will be investigated in a Phase II randomized trial in patients with advanced or metastatic squamous NSCLC.

Study Overview

• Status: Terminated
• Conditions: Squamous Non-small Cell Lung Cancer
• Intervention / Treatment: Drug: Docetaxel; Drug: Buparlisib; Drug: Buparlisib matching placebo

Detailed Description

Based on an overall review of safety and preliminary efficacy data done on 01-Dec-2014 showing marginal anti-tumor activity and newly emerged treatment options, a decision was taken to stop further development of this combination in patients with advanced or metastatic squamous NSCLC and Phase II of the study was not conducted.

• Study Type: Interventional
• Enrollment (Actual): 27
• Phase: Phase 1

Contacts and Locations

Study Locations

• Belgium
  • Charleroi, Belgium, 6000
    • Novartis Investigative Site
  • Mons, Belgium, 7000
    • Novartis Investigative Site
• France
  • Creteil, France, 94000
    • Novartis Investigative Site
  • Saint Herblain cedex, France, 44805
    • Novartis Investigative Site
• Germany
  • Frankfurt, Germany, 60590
    • Novartis Investigative Site
  • Heidelberg, Germany, 69120
    • Novartis Investigative Site
  • Mainz, Germany, 55131
    • Novartis Investigative Site
• Italy
  • MB
    • Monza, MB, Italy, 20900
      • Novartis Investigative Site
• Korea, Republic of
  • Korea
    • Seoul, Korea, Korea, Republic of, 05505
      • Novartis Investigative Site
    • Seoul, Korea, Korea, Republic of, 06351
      • Novartis Investigative Site
• Spain
  • Catalunya
    • Barcelona, Catalunya, Spain, 08036
      • Novartis Investigative Site
• Sweden
  • Stockholm, Sweden, 171 76
    • Novartis Investigative Site
• United States
  • Arkansas
    • Fayetteville, Arkansas, United States, 72703
      • Highlands Oncology Group SC-1
  • Florida
    • Tampa, Florida, United States, 33612
      • H. Lee Moffitt Cancer Center & Research Institute H Lee Moffitt
  • Massachusetts
    • Worcester, Massachusetts, United States, 01608
      • Reliant Medical Group Reliant Medical Group
  • Virginia
    • Norfolk, Virginia, United States, 23502
      • Virginia Oncology Associates Virginia Oncology Assoc. (2)

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patient is an adult ≥ 18 years old at the time of informed consent
• Patient has histologically and/or cytologically confirmed diagnosis of squamous NSCLC. Diagnosis of mixed squamous and non-squamous or adenosquamous NSCLC will be acceptable for enrollment.
• Patient has received one prior approved regimen of platinum-based chemotherapy (excluding a docetaxel-containing regimen) for advanced or metastatic (Stage IIIb or Stage IV) squamous NSCLC, followed by disease progression. A drug provided as maintenance therapy following cytotoxic chemotherapy will be considered to be part of that regimen.

Note: Patients who received paclitaxel therapy are eligible for this trial. •Patient has adequate tumor tissue (either archival or new tumor biopsy) for the analysis of PI3K-related biomarkers.

Enrollment in the Phase II part of the study is contingent on the central laboratory confirming receipt of an adequate amount of tissue including sufficient DNA for analysis.

•Patient has measurable or non-measurable disease according to RECIST version 1.1 criteria.

Phase II only: Patient must have at least one measurable lesion as per RECIST criteria.

• Patient has an ECOG performance status ≤ 1
• Patient has adequate bone marrow and organ function

Exclusion Criteria:

• Patient has received previous treatment with a PI3K or AKT inhibitor
• Patient has symptomatic Central Nervous System (CNS) metastases Patients with asymptomatic CNS metastases may participate in this trial. The patient must have completed prior local treatment, if any, for CNS metastases ≥ 28 days prior to the start of study treatment (including radiotherapy and/or surgery, or ≥ 14 days for stereotactic radiosurgery).
• Patient has a score ≥ 12 on the PHQ-9 questionnaire.
• Patient selects a response of "1, 2 or 3" to question number 9 on the PHQ-9 questionnaire regarding potential for suicidal thoughts or ideation (independent of the total score of the PHQ-9).
• Patient has a GAD-7 mood scale score ≥ 15.
• Patient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation or patients with active severe personality disorders.
• Patient has ≥ CTCAE grade 3 anxiety

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Phase Ib: Buparlisib + docetaxel; Buparlisib (BKM120) oral once daily: 80 mg and 100 mg dose levels to be tested in the dose escalation part of the trial in combination with docetaxel every three week intravenous (i.v.) infusion: 75 mg/m2 as per label.	Drug: Docetaxel; Drug: Buparlisib; Other Names: BKM120
EXPERIMENTAL: Phase II: Buparlisib + docetaxel; Buparlisib oral once daily: MTD/RP2D mg to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.	Drug: Docetaxel; Drug: Buparlisib; Other Names: BKM120
PLACEBO_COMPARATOR: Phase II: Placebo + docetaxel; Buparlisib matching placebo oral once daily to be tested in combination with docetaxel every three week i.v. infusion: 75 mg/m2 as per label.	Drug: Docetaxel; Drug: Buparlisib matching placebo

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Phase Ib: Incidence of Dose Limiting Toxicities (DLTs) in Cycle 1	To determine the maximum tolerated dose/recommended phase ll dose (MTD/RP2D) of buparlisib in combination with docetaxel by assessing the incidence of DLTs in Cycle 1; Cycle 1 = 21 days	Day 21
Phase II: Progression Free Survival (PFS)	PFS as per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. To estimate the treatment effect of docetaxel and buparlisib or placebo on PFS in patients with advanced or metastatic squamous NSCLC.	After 70 PFS events have been observed at 9 months after patient enrollment

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of patients with at least one adverse event.		Up to 30 days after the last dose
Number of patients with laboratory abnormalities.		Up to 30 days after the last dose
Overall Survival (OS)	Overall survival (OS) time is measured from the start of study drug to the date of death due to any cause. If a patient is not known to have died, survival will be censored at the date of last contact. Data will be collected post treatment every 6 weeks until approximately 75% of patients have reached the survival endpoint (Phase I + Phase II)	Treatment start (phase Ib)/randomization (phase II), every 6 weeks to the date of first document progression for up to 3 years
Overall response rate (ORR)	Overall response is the number of participants who had a complete response (CR) or a partial response (PR) based on local investigator's assessment of RECIST 1.1 criteria.	Every 6 weeks from randomization until first documented progression for up to 3 years
Time to response (ToR)	Time to overall response is defined as the time from the date of first drug intake in Phase Ib and from the date of randomization in Phase II to the date of first documented response.	Every 6 weeks from randomization until first documented progression for up to 3 years
Duration of response (DR)	Duration of overall response is defined as the elapsed time between the date of first documented response and the following date of event defined as the first documented progression or death due to underlying cancer.	Every 6 weeks from randomization until first documented progression for up to 3 years
Change in electrocardiogram (ECG) and cardiac imaging		Up to 30 days after the last dose
Changes in vital signs		Up to 30 days after the last dose
Shift in ECOG performance status	cycle = 21 days; end of treatment is defined as 15 days after treatment discontinuation; There is no treatment duration as patients continue to receive drug till toxicity or they withdraw consent	Baseline, worst post-baseline result at day 1 of every cycle and at end of study treatment (3 years)
Change in Mood scales		Up to 30 days after the last dose
Time to definitive 10% deterioration in the global health status/quality of life (QOL) scale score of the EORTC QLQ-C30	Date of event is defined as at least 10% relative to baseline worsening of the corresponding scale score or death due to any cause	Baseline, Every 6 weeks until disease progression for up to 3 years
Change in the global health status/quality of life (QOL) scale score of the EORTC QLQ-C30	Change in the domain scores	Baseline, Every 6 weeks until disease progression for up to 3 years
Docetaxel and buparlisib plasma concentrations		Cycle 1 day 8 and 15, Cycle 2-Cycle n day 1
PFS Phase Ib	PFS as per RECIST 1.1	at 3 months after patient enrollment, every 6 weeks until disease progression for up to 3 years

Collaborators and Investigators

• Sponsor: Novartis Pharmaceuticals

Study record dates

Study Major Dates

• Study Start: October 1, 2013
• Primary Completion (ACTUAL): August 1, 2015
• Study Completion (ACTUAL): August 1, 2015

Study Registration Dates

• First Submitted: May 16, 2013
• First Submitted That Met QC Criteria: July 26, 2013
• First Posted (ESTIMATE): July 30, 2013

Study Record Updates

• Last Update Posted (ACTUAL): August 14, 2018
• Last Update Submitted That Met QC Criteria: August 12, 2018
• Last Verified: August 1, 2018

More Information

Terms related to this study

• Keywords: Docetaxel; NSCLC; Metastatic; Stage IV; BKM120; PI3K inhibitor; Squamous non-small cell lung cancer; Buparlisib; Stage IIIb
• Additional Relevant MeSH Terms: Respiratory Tract Diseases; Neoplasms; Lung Diseases; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents; Tubulin Modulators; Antimitotic Agents; Mitosis Modulators; Docetaxel
• Other Study ID Numbers: CBKM120D2205; 2013-000833-11 (EUDRACT_NUMBER)